OMNIAB, INC. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
OMNIAB, INC. (OABI) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $34.10 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2026-08-06
- OMNIAB, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-06-30 was $16.10M, a 9.55% decline year-over-year.
- OMNIAB, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-03-31 was $18.00M, a 89.47% increase year-over-year.
- OMNIAB, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-12-31 was $11.00M, a 24.14% decline year-over-year.
- OMNIAB, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-09-30 was $12.50M, a 3.85% decline year-over-year.
- OMNIAB, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2025 was $50.80M, a 34.87% decline from fiscal 2024.
- OMNIAB, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2024 was $78.00M, a 19.50% decline from fiscal 2023.
- OMNIAB, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2023 was $96.90M.
- OMNIAB, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2022 was $0.00.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $34.10M 10-Q · filed 2026-08-06 | $45.10M derived: sum of 3 quarters · filed 2026-08-06 | $57.60M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $18.00M 10-Q · filed 2026-05-07 | $29.00M derived: sum of 2 quarters · filed 2026-05-07 | $41.50M derived: sum of 3 quarters · filed 2026-05-07 | $59.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $11.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $23.50M derived: sum of 2 quarters · filed 2026-03-04 | $41.30M derived: sum of 3 quarters · filed 2026-08-06 | $50.80M 10-K · filed 2026-03-04 |
| 2025-09-30 | $12.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $30.30M derived: sum of 2 quarters · filed 2026-08-06 | $39.80M 10-Q · filed 2025-11-04 | $54.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $17.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $27.30M 10-Q · filed 2026-08-06 | $41.80M derived: sum of 3 quarters · filed 2026-08-06 | $54.80M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $9.50M 10-Q · filed 2026-05-07 | $24.00M derived: sum of 2 quarters · filed 2026-05-07 | $37.00M derived: sum of 3 quarters · filed 2026-05-07 | $61.50M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $14.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $27.50M derived: sum of 2 quarters · filed 2026-03-04 | $52.00M derived: sum of 3 quarters · filed 2026-03-04 | $78.00M 10-K · filed 2026-03-04 |
| 2024-09-30 | $13.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $37.50M derived: sum of 2 quarters · filed 2025-11-04 | $63.50M 10-Q · filed 2025-11-04 | $94.15M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $24.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $50.50M 10-Q · filed 2025-08-06 | $81.15M derived: sum of 3 quarters · filed 2025-08-06 | $117.40M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $26.00M 10-Q · filed 2025-05-08 | $56.65M derived: sum of 2 quarters · filed 2025-05-08 | $92.90M derived: sum of 3 quarters · filed 2025-05-08 | $118.90M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $30.65M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $66.90M derived: sum of 2 quarters · filed 2025-03-18 | $92.90M derived: sum of 3 quarters · filed 2025-03-18 | $96.90M 10-K · filed 2025-03-18 |
| 2023-09-30 | $36.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $62.25M derived: sum of 2 quarters · filed 2024-11-12 | $66.25M 10-Q · filed 2024-11-12 | $66.25M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $26.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $30.00M 10-Q · filed 2024-08-08 | $30.00M derived: sum of 3 quarters · filed 2024-08-08 | $30.00M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $4.00M 10-Q · filed 2024-05-09 | $4.00M derived: sum of 2 quarters · filed 2024-05-09 | $4.00M derived: sum of 3 quarters · filed 2024-05-09 | $4.00M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $0.00 derived: sum of 2 quarters · filed 2024-03-25 | $0.00 derived: sum of 3 quarters · filed 2024-03-25 | $0.00 10-K · filed 2024-03-25 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |